# Progress Note 04 — Annual Wellness Visit, Subsequent

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Ida B. Wells (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET022-SYN-TD
- Date: 1931-02-17
- Fictional facility: St. Posthumous Health Center
- Fictional author: Cordelia Ashworth-Banks, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Annual Wellness Visit, Subsequent
- Services: HCPCS G0439 (subsequent annual wellness visit) with CPT 99497 (advance care planning), both on the same day

## Chief complaint

Subsequent annual wellness visit. **S**

## History of present illness

Mrs. Wells comes for her subsequent annual wellness visit two weeks after starting dapagliflozin and four weeks after starting losartan for chronic kidney disease G3b A2 with hypertension. She has had no dizziness, faintness or genital itching and passes a little more urine than before. Her home blood pressure readings average 134/80. Her ankles no longer swell by evening, and she is less tired in the afternoons. Acetaminophen controls her knee aching and she has taken no naproxen since the first visit. Last week she went to the kidney education session at the health center, brought a page of questions, and asked to spend part of today on what the treatment options would mean for her if her kidneys failed one day. She has had no falls, emergency visits or hospital stays in the past year. **S**

| Element | Detail |
|---|---|
| Visit | Subsequent annual wellness visit, age 68 |
| New medicines | Losartan for four weeks and dapagliflozin for two, without side effects |
| Home blood pressure | Average 134/80 |
| Symptoms | Ankle swelling gone; less tired |
| Safety events | No falls, emergency visits or hospital stays |

## Health risk assessment

Completed by her on paper before the visit and reviewed with her by Dr. Ashworth-Banks. **S**

| Domain | Finding |
|---|---|
| Self-rated health | Fair; better than a month ago |
| Psychosocial | Lives with her husband; a wide circle of colleagues and readers; busy with writing and civic work; stress from deadlines is manageable |
| Behavioral | Never smoker; under one drink a week; walks most days; cutting salt with help from the dietitian; sleeps about six and a half hours |
| Activities of daily living | Independent in bathing, dressing, eating, toileting and transfers |
| Instrumental activities of daily living | Manages her own medicines, money, correspondence and travel |
| Home safety | Smoke detectors working; handrail on the front steps; no loose rugs |
| Hearing and vision | Hears well; reading glasses; last eye examination more than two years ago |
| Bladder | Passes a little more urine since dapagliflozin; no leakage |
| Memory | No concerns |
| Health care experiences | Wants to see the evidence and the numbers; says she was once told a kidney result was normal without anyone explaining how it was calculated |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tiredness in the afternoons, less than before; weight down 1.2 kg since intake |
| Eyes | Negative | No change in vision with reading glasses |
| Ears, nose, mouth, and throat | Negative | No hearing difficulty; no mouth sores |
| Cardiovascular | Negative | No chest pain, palpitations or ankle swelling |
| Respiratory | Negative | No cough or breathlessness |
| Gastrointestinal | Negative | No nausea, poor appetite or blood in the stool |
| Genitourinary | Negative | No burning, genital itching or blood in the urine |
| Musculoskeletal | Positive | Knee aching on stairs, controlled with acetaminophen |
| Integumentary | Negative | No itching or rash |
| Neurological | Negative | No dizziness on standing, numbness or memory change |
| Psychiatric | Negative | Mood steady; PHQ-2 0 |
| Breast | Negative | No lump or nipple change |

12 systems reviewed. **S**

## Current medications

- Acetaminophen 500 mg oral tablet, one or two tablets up to three times a day as needed for knee aching (no more than 3,000 mg a day), in place of naproxen **S**
- Losartan 50 mg oral tablet, one tablet daily; hold on days of vomiting, diarrhea or not eating **S**
- Atorvastatin 20 mg oral tablet, one tablet daily **S**
- Cholecalciferol (vitamin D3) 25 mcg (1,000 units) oral tablet, one tablet daily **S**
- Dapagliflozin 10 mg oral tablet, one tablet daily; hold on days of vomiting, diarrhea or not eating, and before surgery **S**

## Allergies

- No known allergy **S**

## Objective

BP 136/82 mmHg; pulse 72 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 97% on room air; weight 69.2 kg; BMI 28.1 kg/m². All vital signs are synthetic.

PHQ-2: 0; Mini-Cog: 5; AUDIT-C: 1. All results are synthetic.

## Immunizations given today

- Hepatitis B vaccine (HepB-CpG), dose 2 of 2 **S**
- Respiratory syncytial virus vaccine, adjuvanted (RSVPreF3), single dose **S**
- Recombinant zoster vaccine, dose 1 of 2 **S**

## Physical examination

| System | Finding |
|---|---|
| Constitutional | Well; weight 69.2 kg; blood pressure 136/82 seated and 132/80 standing, without symptoms |
| Eyes | Near vision 20/30 with reading glasses; undilated fundi show mild arteriolar narrowing |
| Ears | Whispered-voice test passed in both ears |
| Neck | No thyroid enlargement or nodes; no carotid bruits |
| Cardiovascular | Regular rhythm; no murmur; no ankle swelling |
| Respiratory | Clear |
| Abdomen | Soft; no masses or bruits |
| Musculoskeletal | Crepitus in both knees without effusion; Timed Up and Go 11 seconds with a steady gait |
| Neurological | Oriented; Mini-Cog 5 of 5 (recall 3 of 3, clock normal) |
| Skin | No suspicious lesions |
| Psychiatric | Engaged, exact and well informed; judgment intact |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Subsequent annual wellness visit completed**. Health risk assessment reviewed, prevention plan updated and a written copy given. Depression, alcohol, cognitive and fall-risk screens are negative. **S**
   - Mammogram and bone density scan ordered.
   - Stool immunochemical test kit given.
   - Eye examination with her optometrist, with a dilated view of the retina for hypertensive changes.
   - Next annual wellness visit in one year.
2. **Chronic kidney disease G3b A2** (N18.32). Tolerating losartan and dapagliflozin; ankle swelling resolved. Potassium and creatinine are due at four weeks on dapagliflozin, at the next visit. She has been taught the options for kidney failure well before any decision is needed. **S**
   - Potassium and creatinine at the review in two weeks.
   - Continue sick-day rules for losartan and dapagliflozin.
3. **Hypertension with chronic kidney disease** (I12.9). Home average 134/80, not yet below 130/80; no orthostatic drop. **S**
   - Continue home readings twice a day for the week before the next visit.

## Personalized prevention plan

A written copy was given to the patient. **S**

| Service | Status | Detail |
|---|---|---|
| Depression screening | Completed today | PHQ-2 score 0 |
| Alcohol misuse screening | Completed today | AUDIT-C score 1 |
| Cognitive assessment | Completed today | Mini-Cog 5 of 5 |
| Falls prevention | Completed today | No falls; Timed Up and Go 11 seconds; home safety reviewed |
| Breast cancer screening | Ordered | Mammogram every two years to 74; last one more than two years ago |
| Colorectal cancer screening | Ordered | Stool immunochemical test, her choice, to avoid bowel preparation fluids and sedation while her kidney medicines are new |
| Bone density (DXA) | Ordered | Women 65 and older; none on record; kidney disease adds to fracture risk |
| Hepatitis C and HIV screening | Up to date | Both negative with the kidney tests last month |
| Influenza vaccine, this season | Up to date | High-dose vaccine last month |
| Pneumococcal vaccine | Up to date | PCV20 last month; no further doses |
| Hepatitis B vaccine | Completed today | Dose 2 of HepB-CpG today; series complete; antibody check after the series because of kidney disease |
| RSV vaccine | Completed today | Single dose for an adult under 75 with chronic kidney disease |
| Recombinant zoster vaccine | Completed today | Dose 1 today; dose 2 in two to six months |
| COVID-19 vaccine, this season | Due | At the next visit, to space the vaccines at her request |
| Tetanus booster | Up to date | Tdap six years ago |
| Eye examination | Due | More than two years since the last; dilated examination for hypertensive retinal changes |
| Lung cancer and abdominal aortic aneurysm screening | Not indicated | Never smoker |
| Cervical cancer screening | Not indicated | Not recommended after 65 with adequate prior screening, which she reports |

## Advance care planning

Voluntary advance care planning discussion of about 25 minutes, with her consent, building on the kidney education session. She understands that her kidney disease is at stage G3b and that, with treatment, most people at her stage do not reach kidney failure; the estimate of her own 5-year risk was explained as about 7 in 100. If her kidneys were to fail, she would want to be assessed for a transplant, would prefer home dialysis to center dialysis if dialysis were needed, and wants conservative kidney management explained to her again before any choice is made. She wants full treatment for illness that can be reversed. She has named a health care agent, recorded in the confidential part of the chart and not named here. To be revisited yearly, at any sustained fall in eGFR below 20, or after a serious illness. **S**

## Guideline basis

- KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024), Kidney Disease: Improving Global Outcomes (Kidney International)
- Adult Immunization Schedule by Age (2026), Centers for Disease Control and Prevention
- Medicare Wellness Visits (Medicare Learning Network) (2026), Centers for Medicare & Medicaid Services
- Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026), Aether Forge
- Breast Cancer: Screening (2024), U.S. Preventive Services Task Force
- Colorectal Cancer: Screening (2021), U.S. Preventive Services Task Force
- Osteoporosis to Prevent Fractures: Screening (2025), U.S. Preventive Services Task Force
- Falls Prevention in Community-Dwelling Older Adults: Interventions (2024), U.S. Preventive Services Task Force

## Follow-up

- Review in two weeks with potassium and creatinine. Mammogram, bone density scan and stool test as ordered. Next annual wellness visit in one year. **S**
- Next scheduled visit 1931-03-03: four weeks after starting dapagliflozin: potassium, creatinine and blood pressure, the losartan dose, and the plan for the months ahead. **S**
